Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

Phase 1CompletedNCT01737424

LG Life Sciences89 enrolled

Overview

To investigate the safety, tolerability and pharmacokinetic characteristics of LC28-0126 in healthy male subjects

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

LC28-0126DRUG

LC28-0126

PlaceboDRUG

Placebo

Eligibility

Sex: MALEMin age: 20 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male subjects between the ages of 20 and 45 years at screening. * Subjects with BMI between 18.0(inclusive) and 27.0 kg/m2 (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive) Exclusion Criteria: * Participation in a clinical research study within the previous 2 months * Regular alcohol consumption \>21 units per week.

Locations (1)

Seoul National University Hospital, Clinical Trial Center

Seoul, South Korea

Outcomes

Primary Outcomes

Adverse events

Time frame: 12 days

Secondary Outcomes

Cmax

Time frame: up to 6 days post-dose

AUC

Time frame: up to 6 days post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.